Side-by-side comparison of AI visibility scores, market position, and capabilities
Proprio builds the Paradigm AI surgical guidance platform, providing radiation-free 3D real-time anatomy visualization and intraoperative spinal alignment measurements for spine surgeons.
Proprio is a Seattle-based surgical technology company founded in 2016 by CEO Gabriel Jones alongside neurosurgeon Dr. Samuel Browd, University of Washington Professor Joshua Smith, and computer vision specialist James Youngquist. The company develops Paradigm, an FDA-cleared AI surgical guidance platform that uses light-field imaging, optical tracking, depth sensors, and infrared cameras to build a real-time 3D model of the surgical field without ionizing radiation.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.